Optimising Patient Outcomes Throughout the Rheumatoid Arthritis Patient Journey: The Exception, the Standard, and the Rule

This satellite symposium took place on 10th June 2016, as a part of the European League Against Rheumatism (EULAR) 17th annual congress in London, UK

Chairperson: Peter Taylor1
Speakers: Ronald van Vollenhoven,2 Peter Taylor,1 Daniel Aletaha3

1. University of Oxford, Botnar Research Centre, Oxford, UK
2. Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
3. Medical University of Vienna, Vienna, Austria

Disclosure: Prof Taylor has received consulting fees, research or institutional support, and educational grants from AbbVie, Baxalta, Biogen, Bristol-Meyers Squibb, Celgene, Celltrion, Epirus, Galapagos, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. Prof van Vollenhoven has received consulting fees, research or institutional support, and educational grants from AbbVie, Amgen, Biotest, Bristol-Meyers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex. Prof Aletaha has received consulting fees, research or institutional support and educational grants from AbbVie, Bristol-Meyers Squibb, Eli Lilly, Grünenthal, Janssen, Merck, Pfizer, Sanofi/ Regeneron, and UCB.
Acknowledgements: Writing assistance was provided by Melanie Sweetlove of ApotheCom.
Support: The symposium and this article were sponsored and reviewed by UCB Pharma. The views and opinions expressed are those of the authors and not necessarily of UCB Pharma.
Citation: EMJ Rheumatol. 2016;3[1]36-47.

Meeting Summary

Prof Peter Taylor opened the symposium focussed on optimisation of treatment for rheumatoid arthritis (RA) at each stage of the patient’s journey. Prof Ronald van Vollenhoven reviewed the evidence for first- line biologics in the ‘exceptional patient’ and explored which patients may be suitable for such treatments. Prof Taylor then expanded on how use of such treatments could be optimised and when to introduce biologic therapy for the so-called ‘standard’ patient. Finally, Prof Daniel Aletaha discussed treatment options and targets for patients who have failed on a biologic as ‘the rule’ in the treatment of RA.

Download (PDF, 240KB)

Comments are closed.